A144510 Stock Overview
Develops cell therapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GC Cell Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,950.00 |
| 52 Week High | ₩48,800.00 |
| 52 Week Low | ₩21,250.00 |
| Beta | 0.93 |
| 1 Month Change | -4.58% |
| 3 Month Change | -27.31% |
| 1 Year Change | -44.75% |
| 3 Year Change | -75.95% |
| 5 Year Change | -36.81% |
| Change since IPO | -50.21% |
Recent News & Updates
The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%
Dec 01
Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price
Oct 14Is GC Cell (KOSDAQ:144510) A Risky Investment?
Sep 08Recent updates
The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%
Dec 01Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share Price
Oct 14Is GC Cell (KOSDAQ:144510) A Risky Investment?
Sep 08We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative
Mar 19We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its Debt
Feb 22Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?
Jan 18
Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?
Dec 14Shareholder Returns
| A144510 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.0% | -2.3% | -1.9% |
| 1Y | -44.8% | 14.9% | -9.5% |
Return vs Industry: A144510 underperformed the KR Biotechs industry which returned 16.3% over the past year.
Return vs Market: A144510 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A144510 volatility | |
|---|---|
| A144510 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A144510 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A144510's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 752 | James Park | www.gccell.com |
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC.
GC Cell Corporation Fundamentals Summary
| A144510 fundamental statistics | |
|---|---|
| Market cap | ₩359.90b |
| Earnings (TTM) | -₩3.39b |
| Revenue (TTM) | ₩184.36b |
2.0x
P/S Ratio-106.2x
P/E RatioIs A144510 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A144510 income statement (TTM) | |
|---|---|
| Revenue | ₩184.36b |
| Cost of Revenue | ₩137.39b |
| Gross Profit | ₩46.96b |
| Other Expenses | ₩50.35b |
| Earnings | -₩3.39b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -225.49 |
| Gross Margin | 25.48% |
| Net Profit Margin | -1.84% |
| Debt/Equity Ratio | 11.9% |
How did A144510 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-44%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 07:05 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GC Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jinhee Kwak | Eugene Investment & Securities Co Ltd. |
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |